Endra Life Sciences Inc (NDRA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
3.98 +0.53 (+15.36%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 3.90 -0.08 (-2.01%) 19:57 ET
for Fri, Apr 25th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -11,508 | -10,060 | -13,179 | -11,231 | -11,726 |
Depreciation Amortization | 206 | 276 | 234 | 224 | 398 |
Other Working Capital | 134 | -923 | -1,026 | -1,261 | -1,521 |
Other Operating Activity | 3,767 | 1,159 | 1,201 | 1,146 | 2,102 |
Operating Cash Flow | $-7,401 | $-9,549 | $-12,769 | $-11,122 | $-10,747 |
Cash Flows From Investing Activities | |||||
PPE Investments | -13 | -25 | -203 | -45 | -75 |
Investing Cash Flow | $-13 | $-25 | $-203 | $-45 | $-75 |
Cash Flows From Financing Activities | |||||
Debt Issued | N/A | N/A | N/A | N/A | 337 |
Common Stock Issued | 7,837 | 7,518 | 8,400 | 13,402 | 11,538 |
Other Financing Activity | -29 | 0 | 0 | 0 | 0 |
Financing Cash Flow | $7,809 | $7,518 | $8,400 | $13,402 | $11,875 |
Beginning Cash Position | 2,834 | 4,889 | 9,462 | 7,227 | 6,174 |
End Cash Position | 3,230 | 2,834 | 4,889 | 9,462 | 7,227 |
Net Cash Flow | $396 | $-2,055 | $-4,572 | $2,234 | $1,053 |
Free Cash Flow | |||||
Operating Cash Flow | -7,401 | -9,549 | -12,769 | -11,122 | -10,747 |
Capital Expenditure | -16 | -34 | -203 | -45 | -75 |
Free Cash Flow | -7,417 | -9,583 | -12,972 | -11,167 | -10,822 |